Trevi Therapeutics Inc TRVI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $13.46
- Day Range
- $13.52–14.78
- 52-Week Range
- $5.41–16.12
- Bid/Ask
- $13.65 / $15.30
- Shares Outstanding
- 141.98M
- Market Cap
- $2.02B
- Volume/Avg
- 2M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 34
Valuation
|
Metric
|
TRVI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 10.04 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TRVI
|
|---|---|
Quick Ratio | 24.14 |
Current Ratio | 24.75 |
Interest Coverage | — |
Quick Ratio
TRVI
Profitability
|
Metric
|
TRVI
|
|---|---|
Return on Assets (Normalized) | −22.22% |
Return on Equity (Normalized) | −23.40% |
Return on Invested Capital (Normalized) | −27.47% |
Return on Assets
TRVI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Ntlfztxz | Nflqnh | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gkbrvrwg | Zbtqg | $64B | |||
| argenx SE ADR
ARGX
| Zvpbvnxp | Lttr | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nncgkcfwx | Fxvktc | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Ykylflhrtn | Rwtdzy | $24B | |||
| BioNTech SE ADR
BNTX
| Tdzqhyxr | Xxxbq | $23B | |||
| Incyte Corp
INCY
| Ynkddjw | Hnlv | $22B | |||
| Moderna Inc
MRNA
| Dwvydnf | Hxn | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Jzxtwvd | Fywv | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Bnmhxlky | Rcq | $13B |
United States